Ligand-based design, synthesis, and experimental evaluation of novel benzofuroxan derivatives as anti-Trypanosoma cruzi agents

European Journal of Medicinal Chemistry

Volumn 64, Issue , 2013, Pages 200-214

  Jorge, Salomão Dória ^a   Palace Berl, Fanny ^a   Mesquita Pasqualoto, Kerly Fernanda ^b   Ishii, Marina ^a   Ferreira, Adilson Kleber ^b   Berra, Carolina Maria ^b   Bosch, Rosemary Viola ^b   Maria, Durvanei Augusto ^b   Tavares, Leoberto Costa ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b INSTITUTO BUTANTAN   (Brazil)

Author keywords

Benzofuroxan derivatives; Exploratory data analysis; External prediction; QSAR approaches; Trypanosoma cruzi

Indexed keywords

4 BUTOXY(BENZOFUROXAN 5 YL)METHYLENE BENZHYDRAZIDE; 4 BUTYL(BENZOFUROXAN 5 YL)METHYLENE BENZHYDRAZIDE; 4 ISOPROPYL (BENZOFUROXAN 5 YL)METHYLENE BENZHYDRAZIDE; 4 PROPOXY(BENZOFUROXAN 5 YL)METHYLENE BENZHYDRAZIDE; 4 PROPYL(BENZOFUROXAN 5 YL)METHYLENE BENZHYDRAZIDE; 4 TERT BUTYL(BENZOFUROXAN 5 YL)METHYLENE BENZHYDRAZIDE; ANTITRYPANOSOMAL AGENT; UNCLASSIFIED DRUG;

ANTIPROTOZOAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY TEST; DRUG DESIGN; DRUG SYNTHESIS; EVALUATION; HUMAN; HUMAN CELL; HYDROPHOBICITY; IC 50; PREDICTION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION; TRYPANOSOMA CRUZI;

BENZOXAZOLES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DESIGN; FIBROBLASTS; HUMANS; LIGANDS; MODELS, MOLECULAR; MOLECULAR STRUCTURE; PARASITIC SENSITIVITY TESTS; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; TRYPANOCIDAL AGENTS; TRYPANOSOMA CRUZI;

EID: 84877034984     PISSN: 02235234     EISSN: 17683254     Source Type: Journal    
DOI: 10.1016/j.ejmech.2013.03.053     Document Type: Article

References (80)

1. N.J. Garg Global health: neglected diseases and access to medicines Infect. Dis. Clin. N. Am. 25 2011 639 651
2. M. Moran, J. Guzman, R. Liyanage, L. Wu, E. Chin, N. Chapman, L. Abela-Oversteegen, D. Gouglas, and D. Kwong Neglected Disease Research and Development: A Five Year Review 2012 Policy Cures London
3. J. Castro, M. de Mecca, and L. Bartel Toxic side effects of drugs used to treat Chagas' disease (American trypanosomiasis) Hum. Exp. Toxicol. 25 2006 471
4. B. Zingales, S.G. Andrade, M.R.S. Briones, D.A. Campbell, E. Chiari, O. Fernandes, F. Guhl, E. Lages-Silva, A.M. Macedo, and C.R. Machado A new consensus for Trypanosoma cruzi intraspecific nomenclature: second revision meeting recommends TcI to TcVI Mem. Inst. Oswaldo Cruz 104 2009 1051 1054
5. M.J.O. Toledo, A.L.F. Guilherme, J.C. Silva, M.V. GasperiI, A.P. Mendes, M.L. Gomes, and S.M. Araujo Trypanosoma cruzi: chemotherapy with benznidazole in mice inoculated with strains from Parana state and from different endemic areas of Brazil Rev. Inst. Med. Trop. São Paulo 39 1997 283 290
6. L.S. Filardi, and Z. Brener Susceptibility and natural resistance of Trypanosoma cruzi strains to drugs used clinically in Chagas disease Trans. R. Soc. Trop. Med. Hyg. 81 1987 755 759 (Pubitemid 18070985)
7. R. Docampo Sensitivity of parasites to free radical damage by antiparasitic drugs Chem-Biol. Interact. 73 1990 1 27 (Pubitemid 20041146)
8. J.A. Squella, M.E. Letelier, L. Lindermeyer, and L.J. Nunez-Vergara Redox behaviour of nifuroxazide: generation of the one-electron reduction product Chem-Biol. Interact. 99 1996 227 238 (Pubitemid 26048565)
9. J.H. Tocher Reductive activation of nitroheterocyclic compounds Gen. Pharmacol.-Vasc. S. 28 1997 485 487 (Pubitemid 27156906)
10. C. Viodé, N. Bettache, N. Cenas, R.L. Krauth-Siegel, G. Chauvière, N. Bakalara, and J. Périé Enzymatic reduction studies of nitroheterocycles Biochem. Pharmacol. 57 1999 549 557 (Pubitemid 29073333)
11. H. Cerecetto, R. Di Maio, M. González, M. Risso, P. Saenz, G. Seoane, A. Denicola, G. Peluffo, C. Quijano, and C. Olea-Azar 1,2,5-Oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: structure-activity relationships J. Med. Chem. 42 1999 1941 1950 (Pubitemid 29269627)
12. M. Cabrera, M.L. Lavaggi, P. Hernández, A. Merlino, A. Gerpe, W. Porcal, M. Boiani, A. Ferreira, A. Monge, and A.L. de Cerain Cytotoxic, mutagenic and genotoxic effects of new anti-T. cruzi 5- phenylethenylbenzofuroxans. Contribution of phase I metabolites on the mutagenicity induction Toxicol. Lett. 190 2009 140 149
13. H. Cerecetto, and M. González Synthetic medicinal chemistry in Chagas' disease: compounds at the final stage of "hit-to-lead" phase Pharmaceuticals 3 2010 810 838
14. S.D. Jorge, M. Ishii, F. Palace-Berl, A.K. Ferreira, P.L. De-Sá-Júnior, A.A. Oliveira, I. Sonehara, K. Pasqualoto, and L. Tavares Preliminary in vitro evaluation of N′-(benzofuroxan-5-yl) methylene benzohydrazide derivatives as potential anti-Trypanosoma cruzi agents MedChemComm 3 2012 824 828
15. J. Šarlauskas, V. Miliukiene, Ž. Anusevičius, L. Misevičiene, K. Krikštopaitis, A. Nemeikaite-Čeniene, I. Viteniene, and N. Čenas Redox properties and prooxidant cytotoxicity of benzofuroxans: a comparison with nitrobenzenes Chemija 20 2009 109 115
16. A.H. Fairlamb, and A. Cerami Metabolism and functions of trypanothione in the kinetoplastida Annu. Rev. Microbiol. 46 1992 695 729
17. A. Schmidt, and R. Krauth-Siegel Enzymes of the trypanothione metabolism as targets for antitrypanosomal drug development Curr. Top. Med. Chem. 2 2002 1239 1259
18. S.E. Austin, M.O.F. Khan, and K.T. Douglas Rational drug design using trypanothione reductase as a target for anti-trypanosomal and anti-leishmanial drug leads Drug Des. Discov. 16 1999 5 23 (Pubitemid 29408220)
19. R.L. Krauth-Siegel, and G.H. Coombs Enzymes of parasite thiol metabolism as drug targets Parasitol. Today 15 1999 404 409 (Pubitemid 29474924)
20. K. Augustyns, K. Amssoms, A. Yamani, P.K. Rajan, and A. Haemers Trypanothione as a target in the design of antitrypanosomal and antileishmanial agents Curr. Pharm. Des. 7 2001 1117 1141 (Pubitemid 32640573)
21. S. Daunes, and C. D'Silva The therapeutic potential of inhibitors of the trypanothione cycle Expert Opin. Investig. Drugs 11 2002 217 231 (Pubitemid 34144868)
22. W.N. Hunter, S. Bailey, J. Habash, S.J. Harrop, J.R. Helliwell, T. Aboagye-Kwarteng, K. Smith, and A.H. Fairlamb Active site of trypanothione reductase: a target for rational drug design J. Mol. Biol. 227 1992 322 333
23. R.L. Krauth-Siegel, S.K. Meiering, and H. Schmidt The parasite-specific trypanothione metabolism of trypanosoma and leishmania Biol. Chem. 384 2003 539 549 (Pubitemid 36609170)
24. G.A. Holloway, W.N. Charman, A.H. Fairlamb, R. Brun, M. Kaiser, E. Kostewicz, P.M. Novello, J.P. Parisot, J. Richardson, and I.P. Street Trypanothione reductase high-throughput screening campaignidentifies novel classes of inhibitors with antiparasitic activity Antimicrob. Agents Chemother. 53 2009 2824 2833
25. S.F. Altschul, T.L. Madden, A.A. Schäffer, J. Zhang, Z. Zhang, W. Miller, and D.J. Lipman Gapped BLAST and PSI-BLAST: a new generation of protein database search programs Nucleic Acids Res. 25 1997 3389 3402 (Pubitemid 27359211)
26. J.S. Papadopoulos, and R. Agarwala COBALT: constraint-based alignment tool for multiple protein sequences Bioinformatics 23 2007 1073 1079 (Pubitemid 47050558)
27. P.A. Karplus, and G.E. Schulz Substrate binding and catalysis by glutathione reductase as derived from refined enzyme: substrate crystal structures at 2Å resolution J. Mol. Biol. 210 1989 163 180 (Pubitemid 19286595)
28. C.S. Bond, Y. Zhang, M. Berriman, M.L. Cunningham, A.H. Fairlamb, and W.N. Hunter Crystal structure of Trypanosoma cruzi trypanothione reductase in complex with trypanothione, and the structure-based discovery of new natural product inhibitors Structure 7 1999 81 89 (Pubitemid 29159184)
29. S.D. Jorge, A. Masunari, C.O. Rangel-Yagui, K.F.M. Pasqualoto, and L.C. Tavares Design, synthesis, antimicrobial activity and molecular modeling studies of novel benzofuroxan derivatives against Staphylococcus aureus Bioorgan. Med. Chem. 17 2009 3028 3036
30. S.D. Jorge, F. Palace-Berl, A. Masunari, C.A. Cechinel, M. Ishii, K.F.M. Pasqualoto, and L.C. Tavares Novel benzofuroxan derivatives against multidrug-resistant Staphylococcus aureus strains: design using Topliss' decision tree, synthesis and biological assay Bioorgan. Med. Chem. 19 2011 5031 5038
31. K.R. Beebe, R.J. Pell, and M.B. Seasholtz Chemometrics: A Practical Guide 1998 Wiley-Interscience New York
32. C. Hansch, and T. Fujita p-σ-π Analysis. A method for the correlation of biological activity and chemical structure J. Am. Chem. Soc. 86 1964 1616 1626
33. H. Kubinyi QSAR: Hansch Analysis and Related Approaches 1993 VCH New York
34. P. Crivori, G. Cruciani, P.A. Carrupt, and B. Testa Predicting blood-brain barrier permeation from three-dimensional molecular structure J. Med. Chem. 43 2000 2204 2216 (Pubitemid 30354545)
35. G. Cruciani, P. Crivori, P.A. Carrupt, and B. Testa Molecular fields in quantitative structure-permeation relationships: the VolSurf approach J. Mol. Struct. THEOCHEM 503 2000 17 30
36. G. Cruciani, M. Pastor, and W. Guba VolSurf: a new tool for the pharmacokinetic optimization of lead compounds Eur. J. Pharm. Sci. 11 2000 S29 S39
37. L.H.P. Silva, and V. Nussenzweig Sobre uma cepa de Trypanosoma cruzi altamente virulenta para o camundongo branco Folia Clin. Biol. 20 1953 191 208
38. J.F. Faucher, T. Baltz, and K.G. Petry Detection of an "epimastigote-like" intracellular stage of Trypanosoma cruzi Parasitol. Res. 81 1995 441 443
39. V.J. Arán, C. Ochoa, L. Boiani, P. Buccino, H. Cerecetto, A. Gerpe, M. González, D. Montero, J.J. Nogal, and A. Gómez-Barrio Synthesis and biological properties of new 5-nitroindazole derivatives Bioorgan. Med. Chem. 13 2005 3197 3207 (Pubitemid 40462122)
40. A.J. Schvartzapel, L. Zhong, R. Docampo, J.B. Rodriguez, and E.G. Gros Design, synthesis, and biological evaluation of new growth inhibitors of Trypanosoma cruzi (epimastigotes) J. Med. Chem. 40 1997 2314 2322 (Pubitemid 27342566)
41. E. Elhalem, B.N. Bailey, R. Docampo, I. Ujváry, S.H. Szajnman, and J.B. Rodriguez Design, synthesis, and biological evaluation of aryloxyethyl thiocyanate derivatives against Trypanosoma cruzi J. Med. Chem. 45 2002 3984 3999 (Pubitemid 35024300)
42. W. Porcal, P. Hernández, M. Boiani, G. Aguirre, L. Boiani, A. Chidichimo, J.J. Cazzulo, N.E. Campillo, J.A. Paez, and A. Castro In vivo anti-Chagas vinylthio-, vinylsulfinyl-, and vinylsulfonylbenzofuroxan derivatives J. Med. Chem. 50 2007 6004 6015
43. W. Porcal, P. Hernández, L. Boiani, M. Boiani, A. Ferreira, A. Chidichimo, J.J. Cazzulo, C. Olea-Azar, M. González, and H. Cerecetto New trypanocidal hybrid compounds from the association of hydrazone moieties and benzofuroxan heterocycle Bioorgan. Med. Chem. 16 2008 6995 7004
44. A. Merlino, D. Benitez, S. Chavez, J. Da Cunha, P. Hernández, L.W. Tinoco, N.E. Campillo, J.A. Páez, H. Cerecetto, and M. González Development of second generation amidinohydrazones, thio-and semicarbazones as Trypanosoma cruzi-inhibitors bearing benzofuroxan and benzimidazole 1, 3-dioxide core scaffolds MedChemComm 1 2010 216 228
45. M. Ishii, S.D. Jorge, A.A. Oliveira, F. Palace-Berl, I.Y. Sonehara, K.F.M. Pasqualoto, and L.C. Tavares Synthesis, molecular modeling and preliminary biological evaluation of a set of 3-acetyl-2,5-disubstituted-2,3- dihydro-1,3,4-oxadiazole as potential antibacterial, anti-Trypanosoma cruzi and antifungal agents Bioorgan. Med. Chem. 19 2011 6292 6301
46. C. Hansch, A. Leo, S.H. Unger, K.H. Kim, D. Nikaitani, and E.J. Lien Aromatic substituent constants for structure-activity correlations J. Med. Chem. 16 1973 1207 1216
47. F.E. Norrington, R.M. Hyde, S.G. Williams, and R. Wootton Physicochemical-activity relations in practice. 1. Rational and self-consistent data bank J. Med. Chem. 18 1975 604 607
48. Gaussian 03W-revision B.02 for Windows, Version 6 1995-2003 Gaussian Inc. Pittsburgh, PA
49. SYBYL 8.0 for Linux 2007 Tripos, Inc. 1699 South Hanley Rd., St. Louis, MO 63144-2917, USA
50. MARVINVIEW 5.4.0.1 - Free License 1998-2010 ChemAxon Ltd.
51. R. Kiralj, and M. Ferreira Is your QSAR/QSPR descriptor real or trash? J. Chemom. 24 2010 681 693
52. Pirouette 3.11 1990-2003 Infometrix Inc. Woodinville, WA
53. P.C. Mahalanobis On the generalized distance in statistics Proceedings of the National Institute of Sciences of India, New Delhi 1936 49 55
54. Gaussview 3.0 2000-2003 Gaussian Inc. Pittsburgh, PA
55. Viewerlite 5.0 2000 Accelrys Inc.
56. D.B. de Oliveira, and A.C. Gaudio BuildQSAR: a new computer program for QSAR analysis Quant. Struct.-Act. Rel. 19 2003 599 601 (Pubitemid 32267160)
57. A. Arroio, K.M. Honório, and A.B.F. da Silva Propriedades químico-quânticas empregadas em estudos das relações estrutura-atividade Quim. Nova 33 2010 694 699
58. M. Boiani, H. Cerecetto, M. Gonzalez, and J. Gasteiger Modeling anti-Trypanosoma cruzi activity of N-oxide containing heterocycles J. Chem. Inf. Model. 48 2008 213 219 (Pubitemid 351271067)
59. C. Hansch, and R.P. Verma Larvicidal activities of some organotin compounds on mosquito larvae: a QSAR study Eur. J. Med. Chem. 44 2009 260 273
60. R. Kiralj, and M. Ferreira Basic validation procedures for regression models in QSAR and QSPR studies: theory and application J. Braz. Chem. Soc. 20 2009 770 787
61. QSARMODELING, Version 2.0. Theoretical and Applied Chemometrics Laboratory, State University of Campinas, Brazil. .
62. VOLSURF 4.0 2006 Molecular Discovery, Ltd. Pinner, UK (included in Sybyl package)
63. C.G. Fortuna, V. Barresi, G. Berellini, and G. Musumarra Design and synthesis of trans 2-(furan-2-yl) vinyl heteroaromatic iodides with antitumour activity Bioorgan. Med. Chem. 16 2008 4150 4159 (Pubitemid 351484004)
64. C.G. Wermuth The Practice of Medicinal Chemistry 2008 Academic Press Oxford
65. J. Verma, V.M. Khedkar, and E.C. Coutinho 3D-QSAR in drug design-a review Curr. Top. Med. Chem. 10 2010 95 115
66. N. Ayyangar, S.M. Kumar, and K. Srinivasan Facile one-pot synthesis of 2,1,3-benzoxadiazole N-oxide (benzofuroxan) derivatives under phase-transfer catalysis Synthesis 1987 2002 616 618
67. P. Pratim Roy, S. Paul, I. Mitra, and K. Roy On two novel parameters for validation of predictive QSAR models Molecules 14 2009 1660 1701
68. A.K. Ferreira, R. Meneguelo, A. Pereira, F.O.R. Mendonça, G.O. Chierice, and D.A. Maria Anticancer effects of synthetic phosphoethanolamine on Ehrlich ascites tumor: an experimental study Anticancer Res. 32 2012 95 104
69. Hyperchem Program Release 7 for Windows 2002 Hypercube, Inc. Gainesville, FL
70. F.H. Allen The Cambridge Structural Database: a quarter of a million crystal structures and rising Acta Crystallogr. B 58 2002 380 388 (Pubitemid 135702674)
71. B. Pniewska, and M. Januchowski Structural investigation of nifuroxazide, p-hydroxy-N′,-(5-nitrofurfurylidene) benzhydrazide Pol. J. Chem. 72 1998 2629 2634
72. S.W. Ng Low-temperature redetermination of benzofurazan 1-oxide Acta Crystallogr. E 65 2009 o1275
73. D. Doherty MOLSIM: Molecular Mechanics and Dynamics Simulation Software-user's Guide, Version 3.2 1997 The Chem21 Group Inc. Lake Forest
74. J.J.P. Stewart Optimization of parameters for semiempirical methods I. Method J. Comput. Chem. 10 2004 209 220
75. W.F. van Gunsteren, and H.J.C. Berendsen Computer simulation of molecular dynamics: methodology, applications, and perspectives in chemistry Angew. Chem. 29 2003 992 1023
76. C.M. Breneman, and K.B. Wiberg Determining atom-centered monopoles from molecular electrostatic potentials. The need for high sampling density in formamide conformational analysis J. Comput. Chem. 11 2004 361 373
77. H. Kubinyi 3D Qsar in Drug Design Theory Methods and Applications vol. 1 1993 Springer
78. M. Ferreira, A.M. Antunes, M.S. Melgo, and P.L.O. Volpe Quimiometria I: calibração multivariada, um tutorial Quim. Nova 22 1999 724 731
79. M. Ferreira Multivariate QSAR J. Braz. Chem. Soc. 13 2002 742 753 (Pubitemid 36177373)
80. S.H. Unger, and C. Hansch Model building in structure-activity relations. Reexamination of adrenergic blocking activity of. beta.-halo-. beta.-arylalkylamines J. Med. Chem. 16 1973 745 749